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ABSTRACT 
Hemorrhage and hemorrhagic shock instigate intestinal damage and inflammation. Multiple 
components of the innate immune response, including complement and neutrophil infiltration, 
are implicated in this pathology. To investigate the interaction of complement activation and 
other components of the innate immune response during hemorrhage, we treated mice post-
hemorrhage with CR2-fH, a targeted inhibitor of the alternative complement pathway and 
assessed intestinal damage and inflammation 2 h after hemorrhage. In wildtype mice, CR2-fH 
attenuated hemorrhage-induced, mid-jejunal damage and inflammation as determined by 
decreased mucosal damage, macrophage infiltration, LTB4, IL-12p40, and TNF-α production.  
The critical nature of intestinal macrophage infiltration and activation in the response to 
hemorrhage was further determined using mice pre-treated with clodronate containing 
liposomes.  The absence of either macrophages or IL-12p70 attenuated intestinal damage. These 
data suggest that complement activation and macrophage infiltration with IL-12p70 production 
are critical to hemorrhage induced mid-jejunal damage and inflammation. 
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INTRODUCTION   
Hemorrhage decreases blood flow to the intestine and is followed by rapid intestinal damage and 
inflammation, which may initiate a systemic inflammatory response (1-2). The intestinal 
inflammatory response involves multiple components of the innate immune system including 
neutrophils, complement and cytokines (3-5). Hemorrhage-induced inflammation also includes 
activation of macrophages within the liver, spleen and lungs (6-8). However, the specific 
complement activation pathway and the early intestinal effects on macrophage infiltration and 
activation in response to hemorrhage are not well defined.   
 
Comprised of more than thirty proteins in the blood, complement protects the body by removing 
pathogenic microorganisms. Initiated by multiple pathways, complement activation generates C3 
opsonins, chemotactic peptides and the cytolytic terminal membrane attack complex. Antibody 
or lectin deposition on surface membranes initiates the classical and lectin pathways, 
respectively. The spontaneously activated, alternative pathway amplifies the classical and lectin 
pathways. However, excessive complement activation increases susceptibility to infections (9) 
and the amplification induced by the alternative pathway increases pathology in multiple disease 
states (10-11). Treatment with complement inhibitors, C5a receptor antagonist (3) or cobra 
venom factor (12), attenuated hemorrhage-induced intestinal damage without identifying the 
specific initiation pathway. It is likely that the alternative pathway either directly or by 
amplification contributes to hemorrhage-induced tissue damage. During excessive or 
inappropriate complement activation, natural inhibitors protect host cells and tissues. Factor H 
(fH) binds C3b, preventing or dissociating the alternative C3 convertase and the subsequent 
amplification loop. By inhibiting amplification of the classical and lectin pathways, fH is a 
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logical therapeutic for excessive complement activation. In other disease models, complement 
receptor 2 (CR2) targeted fH significantly enhanced the effectiveness of fH by targeting the 
inhibitor to sites of complement activation (13).   
 
Hemorrhage induces neutrophil and macrophage infiltration into the hypoxic intestine (12, 14). 
Multiple studies indicated that a neutrophil response with oxidative burst is critical to 
hemorrhage-induced damage (14-15). Hemorrhage also activates Kupffer cells in the liver and 
macrophages in the spleen (6-7) to release cytokines. A recent study indicated that intestinal 
tissues release the macrophage inflammatory cytokines, tumor necrosis factor –a (TNF), IL-6 
and nitric oxide in response to hemorrhage (12). In addition, inhibition of IL-6 (16) or TNF (17-
18) attenuated hemorrhage-induced inflammation. However, a role of macrophage-produced IL-
12 in the intestinal response to hemorrhage is not well characterized. The proinflammatory IL-
12p70 consists of 2 subunits, IL-12p40 and IL-12p35. IL-12p40 is also a subunit of IL-23, which 
stimulates Th17 cells. In addition, IL-12p40 homodimers directly antagonize both IL-12p70 and 
IL-23 (19). Therefore, hemorrhage-induced macrophage infiltration may control the 
inflammatory process through the production of specific IL-12 components. 
 
We hypothesized that alternative complement activation interacts with macrophage secreted IL-
12 and all three innate immune components are critical for hemorrhage-induced inflammation. 
We show that administering the targeted complement inhibitor, CR2-fH, to mice following 
hemorrhage significantly decreases intestinal damage and inflammation by reducing macrophage 
infiltration and IL-12p40 production. Furthermore, macrophage depletion with clodronate, IL-
12p40 or IL-12p35 depletion attenuated injury and inflammation. In contrast, IL-23p19 depletion 
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did not attenuate injury. Thus inhibition of the alternative complement activation pathway 
attenuates macrophage infiltration and IL-12p70 production during the hemorrhage-induced 
inflammatory response and provides multiple therapeutic targets within the innate immune 
response.  
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Materials and Methods: 
Mice: C57Bl/6J male mice (6-8 wks old) were bred and maintained in the Division of Biology at 
Kansas State University. IL-12p40-/- and IL-12p35-/- mice (N11F32) were obtained from Jackson 
Laboratories and rested 1 wk prior to use in experiments. All mice were housed in a 12-hour 
light-to-dark, temperature-controlled room and allowed food and water ad libitum. All research 
was approved by the Institutional Animal Care and Use Committee and conducted in compliance 
with the Animal Welfare Act and other Federal statutes and regulations concerning animals.   
 
Hemorrhage Protocol: After anesthetizing with ketamine (16 mg/kg) and xylazine (8 mg/kg), a 
drop of 0.5% proparacaine hydrochloride ophthalmic solution was applied to the appropriate eye. 
Mice subjected to hemorrhage sustained removal of 25% total blood volume via the retro-orbital 
sinus as described previously (3, 20). Blood volume removed was determined by weight (grams) 
using the following equation (~25% = wt x 0.02) (3, 20) and completed within five minutes. 
Sham-treated mice were subjected to similar procedures with no blood removal. Body 
temperature of animals was maintained at 37 C using a water-circulating heating pad and all 
procedures were performed with the animals breathing spontaneously. Two hours after 
hemorrhage, mice were euthanized and sera and tissue collected. Mid-jejunal sections (2cm), 
approximately 10 cm distal to the gastroduodenal junction, were collected for histology and 
subsequent analyses. Additional mice underwent the same procedures as above with i.v. 
administration of CR2-fH (17.5uM) five minutes after bleeding. CR2-fH was produced as 
described previously (13). Some mice received neutralizing anti-IL-12p40 (R&D Systems) or 
anti-IL-23p19 (R&D Systems) mAb (mg/kg) i.p. at 1 hr prior to hemorrhage.   
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Histology & Injury Score: After fixation in 10% buffered formalin, paraffin embedded tissue 
sections were cut transversely (8μm) and H&E stained for scoring mucosal injury. Using a six-
tiered scale as described previously (21), the average damage score of mid-jejunum intestine (75-
150 villi) was determined after grading each villus from 0-6 with the following categories: 
Normal villi were assigned a score of zero; villi with tip distortion were assigned a score 1; a 
score of 2 was assigned when Guggenheims’ spaces were present; villi with slight disruption of 
the epithelial cells were assigned a score of 3; a score of 4 was assigned to villi with exposed but 
intact lamina propria; a score of 5 was assigned when the lamina propria was exuding; last, villi 
that displayed hemorrhage or were denuded were assigned a score of 6. 
 
Ex vivo secretions: Ex vivo intestinal supernatants were generated as described previously (3, 
21) and used to determine the secretions released in a 20 min period. Briefly, a 2 cm mid-jejunal 
section was minced, washed, resuspended in 37°C oxygenated Tyrode’s buffer (Sigma-Aldrich) 
and incubated for 20 min at 37oC. Following incubation, the supernatants and tissues were 
collected and stored at -80oC until assayed. After overnight digestion in 0.1M NaOH at 37oC, 
protein content in the intestinal tissue was determined by BCA protein assay (Pierce). Cytokine 
concentrations in the intestinal supernatants were determined with a Milliplex MAP kit 
(Millipore) following the manufacturer's instructions and analyzed using xPONENT 3.1 and 
Analyst (Millipore). Since liposomes interfered with the Milliplex assay, IL-12p40 was also 
determined by ELISA (BioLegend). Leukotriene B4 (LTB4) concentrations in the intestinal 
supernatants were measured using a commercially available enzyme immunoassay kit (Cayman 
Chemicals). All concentrations in the intestinal supernatants were normalized to the total 
intestinal protein content and reported as pg/mg intestinal tissue. Sera C5a concentrations were 
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determined by capture ELISA (BD Biosciences).  
 
Immunohistochemistry: After Sham or hemorrhage treatment, a 2 cm mid-jejunal section was 
frozen in O.C.T. freezing medium and stored at -80oC until used. Intestinal cryosections, (8m) 
were fixed in cold acetone and non-specific binding was blocked using 10% donkey serum in 
PBS. Tissues were stained for C3 deposition using a rat-anti-mouse C3 antibody (Hycult 
Biotechnologies) followed by an appropriate secondary antibody (Jackson Immunoresearch) or 
for F4/80 using directly conjugated rat-anti mouse F4/80 (eBioscience). Serial sections stained 
with isotype control antibodies were used as background. Slides were examined by a blinded 
observer by fluorescent microscopy using a Nikon 80i fluorescent microscope and images 
acquired using a CoolSnapCf camera (Photometrics) and MetaVue Imaging software (Molecular 
Devices).  
 
Macrophage depletion: Infiltrating macrophages were depleted using clodronate liposomes as 
described previously (22-23). Briefly, mice were injected i.v. with 200 l clodronate or PBS 
containing liposomes on days 0, 1, 3, 5 with hemorrhage occurring on day 5 or 6. Liposomes 
were produced using phosphatidylcholine (Lipoid GmbH, Ludwigshafen,Germany) and 
cholesterol (Sigma, St.  Louis, MO). Cl2MDP (clodronate) was a gift of Roche Diagnostics 
GmbH, Mannheim, Germany.   
 
Statistical Analysis: Data are presented as means ± SEM. Differences between treatment groups 
were considered significant if p ≤ 0.05 as determined by one-way ANOVA with a Newman 
Keuls post-hoc test.
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RESULTS 
CR2-fH attenuates hemorrhage-induced mucosal damage and inflammation.   
We verified the ability of CR2-fH to inhibit complement activation by measuring serum C5a in 
wildtype C57Bl/6 and CR2-fH treated mice. As no significant difference was observed between 
Shams from different treatment groups or mouse strains, these data are shown as pooled Shams 
in all graphs. Similar to previous studies (3), serum from hemorrhaged C57Bl/6 mice contained 
significantly more C5a than Sham-treated mice (Fig. 1A). In contrast, C5a was not significantly 
elevated in the serum of CR2-fH treated mice with or without hemorrhage (Fig. 1A), indicating 
that CR2-fH attenuated hemorrhage-induced complement activation. Importantly, administration 
of CR2-fH significantly attenuated intestinal damage in response to hemorrhage (Table 1 and 
Fig. 1E-F). CR2-fH treatment also attenuated the intestinal inflammatory response. Intestinal 
LTB4 production was significantly elevated in hemorrhage-treated mice only in the absence of 
CR2- fH treatment (Fig. 1B). In addition, at 2 h post hemorrhage, C57Bl/6 mice expressed 
significantly elevated levels of intestinal IL-12p40 and TNF-α, and CR2-fH treatment reduced 
these cytokine secretions to the level of Sham treated mice (Fig. 1C-D). These data indicate that 
in a fixed-volume mouse model of hemorrhage, inhibition of the alternative complement 
pathway attenuates the early LTB4 and cytokine response. 
 
Macrophage depletion attenuates hemorrhage-induced intestinal damage and 
inflammation. 
As the above cytokines may be produced by activated macrophages or epithelial cells, we 
hypothesized that hemorrhage induces an infiltration of F4/80+ macrophages in intestinal 
sections. Immunohistochemistry showed few, if any macrophages in the intestinal villi of Sham-
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treated mice (Fig. 2A, G). Intestinal villi from hemorrhage-treated mice contained significantly 
more F4/80+ cells (Fig. 2B, G). Similar to its effect on cytokine levels, CR2-fH significantly 
reduced the number of F4/80+ macrophages infiltrating the villi in response to hemorrhage (Fig.  
2C, G).   
 
To determine if macrophages are required in hemorrhage-induced intestinal injury, we subjected 
mice to hemorrhage after depletion of macrophages with Cl2MDP containing liposomes. 
Immunohistochemistry confirmed macrophage depletion in Cl2MDP treated mice (Fig. 2D, G). 
As indicated in Table 1, macrophage depleted mice did not sustain hemorrhage-induced 
intestinal injury when compared to mice treated with PBS containing liposomes. Similar to 
untreated mice, in response to HS, mice treated with liposomes containing PBS produced 
significant quantities of LTB4 and IL-12p40 (3.2 ± 1.1 and 12 ± 1.11 pg/mg tissue, respectively). 
After treating with liposomes containing Cl2MDP, hemorrhage induced significantly lower 
concentrations of intestinal LTB4 and IL-12p40 (0.98 ± 0.13 and 4.6 ± 1.7 pg/mg tissue, 
respectively) compared to liposomes containing PBS. It was possible that macrophage depletion 
altered the mechanism of intestinal damage. Therefore, we examined C3 deposition in mice 
treated with liposomes containing PBS or Cl2MDP. Compared to Sham-treated mice, intestinal 
sections from mice pre-treated with PBS containing liposomes displayed more C3 deposition 
(Fig. 3A, B). In contrast, C3 deposition was not detected on the intestinal tissue of macrophage-
depleted mice (Fig. 3C).  
 
IL-12p35 RNA expression increases in response to hemorrhage. 
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IL-12 family members, IL-12p70 and Il-23, play a role in other models of intestinal damage (24-
27).  Using real time PCR, we evaluated IL-12p40, IL-12p35 and IL-23p19 mRNA to determine 
the critical family members.  As indicated in Figure 4A, IL-12p40 mRNA was maintained within 
all treatment groups.  In contrast, IL-12p35 was significantly elevated in response to HS in 
wildtype mice and in wildtype mice after treatment with PBS containing liposomes (Fig. 4B).  
However, treatment with fH-CR2 or macrophage depletion eliminated the HS increase in IL-
12p35 RNA (Fig. 4B).  Although IL-23p19 RNA expression increased with HS, complement 
inhibition only altered Il-12p35 RNA expression not production of IL-23p19 RNA expression 
(Fig.  4C).  Clodronate treatment eliminated hemorrhage-induced IL-12p40, IL-12p35 and IL-
23p19 RNA expression (Fig. 4).  These data suggest that HS induces macrophages to produce 
IL-12p70. 
 
IL-12p70 is critical to hemorrhage-induced damage and inflammation. 
To establish if IL-12p70 or IL-23 play key roles in hemorrhage-induced intestinal injury and 
inflammation, we analyzed mucosal damage and complement activation in response to Sham or 
hemorrhage treatment in IL-12p40-/- or IL-12p35-/- mice.  Hemorrhage induced significantly less 
mid-jejunal damage in IL-12p40-/- or IL-12p35-/- mice compared to C57Bl/6 mice (Table 1).  The 
integrity of the villi and intestinal epithelium were maintained in both strains of IL-12 deficient 
mice at 2 h post-hemorrhage (Data not shown).  In response to hemorrhage, intestinal sections 
from IL-12p40-/- mice contained significantly fewer C3 deposits compared to wildtype mice (Fig.  
3D-E).  Similar to Sham treated mice, no C3 deposits were observed on mid-jejunal tissues from 
hemorrhaged IL-12p35-/- mice.  Similarly, the absence of IL-12p40 significantly attenuated 
hemorrhage-induced serum C5a compared to C57Bl/6 mice (138 ± 13 ng/ml and 194 ± 25 ng/ml, 
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respectively).  However, the hemorrhage-induced C5a levels in IL-12p40-/- mice were 
significantly higher than Sham treated mice (76 ± 6 ng/ml).  Thus, IL-12p40-/- and Il-12p35-/- 
mice are protected from intestinal damage with lower levels of complement activation than 
C57Bl/6 mice.  Despite increased macrophage infiltration after hemorrhage (Fig 2E-F), IL-
12p40-/- and IL-12p35-/- mice produced significantly less intestinal LTB4 and TNF- than 
wildtype mice (Fig. 5A-B).   
 
To confirm that IL-12p70 and not IL-23 is a critical intestinal cytokine produced in response to 
HS, we administered either IL-12p40 or IL-23p19 neutralizing antibodies or isotype control 
antibodies to additional wildtype mice.  As indicated in Table 1 and Fig. 5C, anti-mouse IL-
12p40 mAb attenuated intestinal hemorrhage and inflammation similar to that of IL-12p40-/- or 
Il-12p35-/- mice.  Mice receiving Ig control sustained mid-jejunal mucosal damage and 
inflammation similar to wildtype mice.  In contrast, administration of even 100 times the 
neutralizing dose of anti-IL-23p19 specific antibodies did not attenuate intestinal damage, TNF 
or LTB4 production (Table 1 and Fig.  5C).  Together these data suggest that macrophage 
production of IL-12p70 is critical for intestinal damage and inflammation. 
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Discussion   
Although hypothesized to be the motor of systemic inflammation and subsequent mortality, 
intestinal damage and inflammation occurs rapidly (within 2 h) and repair occurs equally quickly 
(within 3-4 h) in the presence or absence of resuscitation (2, 12).  Previous studies concluded that 
the hemorrhage-induced response requires complement activation without identifying the 
specific activation pathway (3, 20, 28-29). The present study indicates that inhibition of the 
alternative complement pathway with CR2-fH attenuates mid-jejunal mucosal damage and 
complement activation in a fixed-volume mouse model of hemorrhage. Complement inhibition 
also decreased the pro-inflammatory intestinal secretions TNF-, IL-12p40 and LTB4. 
Furthermore, pre-treatment with Cl2MDP containing liposomes significantly reduced cytokine 
secretion and attenuated damage and inflammation, suggesting that hemorrhage induces 
macrophage secretion of TNF and IL-12.  Finally, IL-12p40-/- and IL-12p35-/- sustained limited 
to no complement activation or hemorrhage-induced intestinal damage despite an intestinal 
macrophage infiltration. Together, these data suggest that the hemorrhage-induced inflammatory 
response requires complement activation, macrophage infiltration and IL-12 production. 
 
Previous studies showed that systemic blockade of central complement components, C3, C5 or 
C5a, attenuated hemorrhage-induced intestinal damage (3, 30-31). However, each of these 
systemic inhibitors increases the risk of sepsis by blocking multiple complement activation 
pathways. CR2-fH binds tissue-bound C3 activation products and provides local but not systemic 
complement inhibition (13, 32). In addition, when administered early after hemorrhage, CR2-fH 
effectively prevented hemorrhage-induced tissue damage and inflammation.  These results are 
similar to the ability of CR2-fH to attenuate tissue damage in models of collagen induced 
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arthritis, complement-dependent macular degeneration and direct intestinal ischemia/reperfusion 
(13, 32). Treatment with CR2-fH also significantly decreased TNF- mRNA in arthritic joints 
(32), suggesting a decrease in macrophage cytokine production. We extended the anti-
inflammatory properties of CR2-fH to include significantly reducing macrophage infiltration and 
associated cytokines in response to hemorrhage. Although the specific mechanism is not known, 
the alternative complement activation pathway is critical for hemorrhage-induced intestinal 
damage and inflammation.   
 
Within the intestinal mucosa, blood monocytes infiltrate into inflamed tissues to replenish 
mucosal macrophages (33). In response to hemorrhage, macrophage infiltration increased 
significantly within 2 h post-hemorrhage. These data correlate with intestinal production of 
macrophage chemotactic factors which are produced in response to hemorrhage (20). When 
macrophages were depleted with liposomes containing Cl2MDP, intestinal damage, IL-12 and 
LTB4 production were significantly reduced. Similar to these results in the intestine, depletion of 
Kupffer cells by gadolinium chloride significantly reduced hemorrhage-induced liver damage 
(6).  Thus, hemorrhage appears to induce an early excessive innate response by the macrophages. 
 
Macrophage cytokine production mediates the recruitment of innate immune cells and 
coordinates activation of adaptive immune responses. Multiple studies indicate that TNF- and 
IL-6 increase in the serum within 2 h post hemorrhage (6-7, 34). However IL-12 is more 
complex. IL-12p70 is involved in the differentiation of Th cells to the pro-inflammatory Th1 
subset with macrophages and dendritic cells as the primary sources of this cytokine. IL-12p40 
homodimers appear to have regulatory effects and, as a subunit of IL-23, IL-12p40 may induce 
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IL-17 (35). With limited complement activation, hemorrhage of IL-12p40-/- or IL-12p35-/- mice 
resulted in significantly less tissue damage and inflammation.  In addition, hemorrhage induced 
significant damage in mice treated with IL-23p19 neutralizing antibodies. Thus, it appears that 
IL-12p70 is the critical family member in hemorrhage-induced intestinal damage.  
 
In response to hemorrhage, the alternative complement activation pathway induces a macrophage 
infiltrate into the intestine and IL-12 secretion. These data indicate that all three components of 
the innate immune response are required for hemorrhage-mediated mid-jejunal damage. Thus, 
therapeutics targeting local alternative complement activation not only prevent complement 
mediated damage, but also attenuate macrophage activation and cytokine production. 
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FIGURE LEGENDS 
FIGURE 1. Targeted alternative pathway inhibitor attenuates hemorrhage induced 
complement activation, intestinal injury andinflammation. C57Bl/6 (B6) mice subjected to 
Sham or hemorrhage (HS) in the presence or absence of CR2-fH. Serum C5a (A) and ex vivo 
intestinal LTB4 (B), IL-12p40 (C) and TNF- (D) concentrations were determined. 
Representative photomicrographs (original magnification 100X) of H&E stained mid-jejunal 
tissue sections from HS-treated, C57Bl/6 mice with or without administration of CR2-fH (E-F). 
Each bar is the average ± SEM of 4-10 mice per group. (*) Indicates p ≤ 0.05 compared to 
pooled Sham treatment and (indicates p ≤ 0.05 compared to C57Bl/6 HS mice.  
 
FIGURE 2. Macrophages infiltrate into the intestinal tissue following hemorrhage. Mid-
jejunal tissue sections from C57Bl/6 (B6) (A-D), IL-12p40-/- (E) or IL-12p35-/- (F) mice after 
Sham (A) or hemorrhage (HS) (B-F) treated with liposomes containing PBS (B), CR2-fH (C) or 
liposomes containing clodronate (Clod) (D) were stained for F4/80. Photomicrographs original 
magnification of 400X (A-C) or 200X (D-F) are representative of three individual experiments 
with 5-7 photos per treatment group in each experiment. The number of macrophages per villus 
was quantitated from 3-4 mice per treatment group with 20-30 villi per mouse (G). (*) Indicates 
p ≤ 0.05 compared to respective pooled Sham treatment; (indicates p ≤ 0.05 compared to 
C57Bl/6 HS-treated animals. 
 
FIGURE 3. Macrophage or IL-12 depletion inhibits C3 deposition after hemorrhage.  
Mid-jejunal tissue sections from C57Bl/6 (B6) (A-D), IL-12p40-/- (E) or IL-12p35-/- (F) mice 
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after Sham (A) or hemorrhage (HS) (B-F) treated with liposomes containing PBS (B) or 
liposomes containing clodronate (Clod) (C) were stained for C3 deposition. Photomicrographs 
(original magnification of 200X) are representative of three individual experiments with 5-7 
photos per treatment group in each experiment). 
 
FIGURE 4. Complement inhibition or macrophage depletion attenuates hemorrhage 
induced IL-12p35 RNA. C57Bl/6 (B6) mice were subjected to Sham or hemorrhage (HS) after 
inhibition of complement (FH-CR2) or macrophage depletion with liposomes containing 
Clodronate (Clod).  Intestinal RNA transcripts from each treatment group were analyzed for IL-
12p40, IL-12p35 and IL-23p19 by realtime RT-PCR. Each bar represents the average of 4-6 
animals. (*) Indicates p ≤ 0.05 compared to pooled Sham treatment; (indicates p ≤ 0.05 
compared to C57Bl/6 HS-treated animals. 
 
FIGURE 5. IL-12p40 or IL-12p35 but not IL-23p19 deficiency attenuates inflammatory 
cytokine production following hemorrhage. Ex vivo intestinal supernatants were used to 
determine LTB4 (A), and TNF- (B) produced by C57Bl/6 (B6), IL-12p40-/- or IL-12p35-/- mice 
after Sham or hemorrhage (HS) treatment.  One hour after injection of anti-IL-12p40, IL-23p19 
or isotype (Ig) control antibodies, wildtype (B6) mice were subjected to Sham or hemorrhage 
(HS) treatment and intestinal cytokines determined (C). All concentrations were normalized to 
tissue protein content and expressed as pg per mg of intestinal tissue. Each bar represents the 
average of 4-10 animals. (*) Indicates p ≤ 0.05 compared to pooled Sham treatment; (indicates 
p ≤ 0.05 compared to C57Bl/6 HS-treated animals. 
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Table 1. Intestinal Injury Scores 
 
Treatmenta Injury Score ± SEMb 
Pooled Sham 0.47  ± 0.05* 
C57Bl/6 HS 1.99  ± 0.22 
C57Bl/6  + CR2-fH HS 0.58  ± 0.12* 
IL-12p40-/- HS 0.60  ± 0.11* 
IL-12p35-/- HS 0.62  ± 0.05* 
C57Bl/6  + IL-12p40 Ab HS 0.53  ± 0.08* 
C57Bl/6  + IL-23p19 Ab HS 1.99  ± 0.42  
PBS liposomes HS 1.50  ± 0.16 
Clodronate liposomes HS 0.53  ± 0.14** 
 
a.  Mice were subjected to Sham or HS with or without additional treatment as indicated.  After 
euthanization at two hours post hemorrhage, mid-jejunal sections were removed, formalin fixed, 
H&E stained and scored for mucosal injury. 
b.  Data are expressed as mean injury score ± SEM from 4-10 animals per group.  *p< 0.05 
relative to B6 HS. ** p<0.05 relative to PBS liposomes HS. 
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